

PRESS RELEASE

TORSKAL is selected as one of the semi-finalists of the EIT Health Catapult 2022-23 along with 13 other start-ups in the biotech category.

La Réunion, France: June 21, 2022

TORSKAL is also one of the only two French start-ups selected for the European semi-finals of EIT Health Catapult pitch competition in this category.


On 10th June, EIT Health announced the 42 promising start-ups that will go through to the semi-finals of EIT Health Catapult 2022-23 pitch competition, where 14 start-ups each in Biotech, MedTech and Digital Health category will compete against each other. Every year, the competition showcases Europe's most promising start-ups in each of these categories to some of the leading experts and investors.

TORSKAL is selected as one of the 14 start-ups in the biotech category to progress to the semi-finals. TORSKAL also happens to be one of the two French start-ups along with AtmosR to be selected in this category.

What happens next?

During the semi-finals, TORSKAL will present its innovative solution of treating skin cancer using its patented gold nanoparticles combined with Photothermal Therapy to public audience of healthcare professionals, industry experts, investors and many more. Following this, the winners of the semi-finals will receive prizes from the sponsors.

The top three start-ups in each category will be chosen and asked to pitch at a major healthcare event during the finals. They will compete for their share of the €210,000 cash prize as well as the Audience Award. Finally, the winner's name will be placed on the New York Nasdaq Tower.



PRESS RELEASE

TORSKAL is proud and honoured to be among the group of dynamic European start-ups who are working towards bringing a change in the health care sector and looks forward to the semi-finals.

“We are delighted with this selection to the semi-final of the EIT Health Catapult. The program is rich and allows us to be accompanied by excellent mentors on the business, marketing and scientific aspects of our activity.”

says Anne-Laure Morel, Co-founder and President of TORSKAL

About TORSKAL:

The French company was founded in 2015 by two scientists, Anne-Laure Morel, chief scientific officer and president, the inventor of the technology, and Christophe Dugué, managing director and head of regulatory affairs and intellectual property, who joined the company in 2016. The company was founded with the goal of developing green nanoscience from ethical and responsible gold and medicinal plants. Virginie Simon, General Director joined the executive team in 2020 to develop the company internationally.

TORSKAL is a pioneer in green nanotechnology, a precursor in the green chemistry design of new cancer treatments from gold nanoparticles that are produced from a patented method. Their invention is protected by a patent filed in 40 countries covering the synthesis process, the product, and applications in oncology and dermocosmetics.

Their first and main program, the Nanotheranostics - NT1 project aims at treating skin cancers by photothermal therapy, which is a class 3 medical device made of their patented gold nanoparticles designed by green chemistry. The project will enter clinical trials in 2022.

TORSKAL promotes the use of green nanotechnology in therapy and diagnostics, and in industry in general. As a member of the French delegation to the G20YEA, the company is working to ensure that green nanoscience emerges in a sustainable way for the reconstruction of tomorrow.

More information about [TORSKAL](#)

Know more about EIT Health Catapult semi-finalists [here](#)